IPSOGEN And DNAVision Enter In Agreement To Offer In Vitro Diagnostic Tests For Breast Cancer
IPSOGEN And DNAVision Enter In Agreement To Offer In Vitro Diagnostic Tests For Breast Cancer
|
IPSOGEN, a leading molecular diagnostic company based in France and Connecticut, announced that it has signed an agreement with DNAVision, a leading provider of pharmacogenomic services in Europe. With this agreement, IPSOGEN gains the capability to offer its portfolio of breast cancer profiling tests to institutions and patients in a CLIA/ISO17025 certified environment. [click link for full article] |
read more...
News entry number 735 added on Sep 5, 2007 in the Health category.
Comenteaza
Other News in the Health category
Categorie:
Categorie:
Categorie:
Categorie:
Categorie:
Related Links
- Women stop taking breast cancer drugs due to aches and pains: study
- Raloxifene Examined For Breast Cancer Prevention
- FDA Licenses 15 New Blood Typing Tests - Tests Help Ensure Safe Blood Transfusions For Patients
- Starz Entertainment to offer online video service through Verizon
- FDA Approves New Uses For Evista - Drug Reduces Risk Of Invasive Breast Cancer In Postmenopausal
- Would do 'a lot of things' differently over cancer tests: former Eastern Health boss
- Older women unaware of rising breast cancer risk
- More women face breast cancer risk
- LA BioMed Research Finds Simpler Way To Determine Breast Cancer Risk In Postmenopausal Women
News Categories
745
523
480
347
1011
693
280
973
Top 10 News
- Texas Woman Claims to Have Found Mythical 'Chupacabra'
- Google Starts Hosting News on Website
- Study Focuses On Cancer Risk In Biologic Treatment For Rheumatoid Arthritis
- Wireless technology hits security budgets
- Google forced to push image in China
- Ho-hum, the guest's another candidate
- Microsoft purchase of RIM nice to consider, but unlikely
- Western School Board limits digital devices
- 'Spooky' science points to quantum internet
- Nuñez, gov. gamble on healthcare overhaul
Statistics
News:
News Categories:
News Read:
News Categories:
News Read:
5052
8
617
8
617